Perth-based pharmaceutical company Chemeq (ASX:CMQ) has announced that patents on its polymeric molecules to control microbial diseases in livestock have been approved in the US, Europe, Eurasia and China. [ + ]

Melbourne therapeutic vaccine company Virax (ASX:VHL) has taken its hepatitis B treatment into the pre-clinical development phase. [ + ]

Adelaide company TGR Biosciences has received a grant from the Gardiner Foundation to look for bioactives in milk. [ + ]

Gradipore (ASX: GDP) has raised AUD$2.7 million in a placement of six million shares at $0.45 to institutional investors. [ + ]

A groundbreaking international collaboration is quietly underway at The University of New South Wales.

Parents visiting the doctor for an ultrasound of their unborn baby will be able to 'touch' as well as see their baby with new technology being developed at Deakin University.

Can a frog that is known to bury itself in mud for months on end hold the key to avoiding muscle wastage in people with broken bones?

Swinburne TAFE information technology students have created a range of innovative software packages. Two of the packages will influence communications within the Australian Department of Defence and assist in vital research being conducted at Monash University into the structure of proteins.

Researchers are attempting to perfect photosynthesis, a process pioneered by plants and bacteria, in an ambitious scheme to generate new foods, fabrics and even electricity, sustainably.

The genes of a bacterium that can kill or cause permanent organ damage in humans have been identified by Monash University researchers, whose efforts are now focused on finding a suitable vaccine.

Research that has led to new cotton varieties with increased yield and reduced pesticide use has won this year's CSIRO Chairman's Medal.

The big legal guns have fallen silent, and Queensland biotechnology company Benitec (ASX:BLT), CSIRO and Queensland's Department of Primary Industries have shaken hands on a landmark agreement that will allow CSIRO and Benitec to pursue their commercialisation of the revolutionary gene-silencing tool known as DNA-directed RNA interference (ddRNAi). [ + ]

Small biotech companies face investor resistance to mergers and acquisitions, a leading British biotech CEO told attendees at a briefing in Melbourne on Tuesday. [ + ]

New British biotech company Vernalis expects to complete Phase I clinical trials of a powerful new painkiller discovered by Monash University scientists by the middle of next year. [ + ]

Benitec Limited, CSIRO and the Queensland Department of Primary Industries, have announced a strategic agreement that will accelerate Australia's lead in the global commercialisation of DNA Directed RNA interference, a breakthrough gene silencing technology.